These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 31234240

  • 1. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M, Sajatovic M, Kane JM, Cutler AJ, Liang GS, O'Brien CF, Correll CU.
    Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
    [Abstract] [Full Text] [Related]

  • 2. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.
    Am J Psychiatry; 2017 May 01; 174(5):476-484. PubMed ID: 28320223
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):53-60. PubMed ID: 28839340
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM, Correll CU, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):69-76. PubMed ID: 28839342
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF.
    J Clin Psychiatry; 2017 Aug 01; 78(9):1344-1350. PubMed ID: 29141124
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.
    Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O'Brien CF.
    J Clin Psychiatry; 2018 Dec 18; 80(1):. PubMed ID: 30695293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M, Pigato G, Kane JM, Correll CU.
    Drug Des Devel Ther; 2018 Dec 18; 12():1215-1238. PubMed ID: 29795977
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
    Thai-Cuarto D, O'Brien CF, Jimenez R, Liang GS, Burke J.
    Drug Saf; 2018 Apr 18; 41(4):429-440. PubMed ID: 29218680
    [Abstract] [Full Text] [Related]

  • 13. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
    Aggarwal S, Serbin M, Yonan C.
    J Comp Eff Res; 2019 Oct 18; 8(13):1077-1088. PubMed ID: 31464152
    [Abstract] [Full Text] [Related]

  • 14. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F, Luther K, Talreja O.
    Am J Health Syst Pharm; 2020 Jan 24; 77(3):167-174. PubMed ID: 31974564
    [Abstract] [Full Text] [Related]

  • 15. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H, Henchcliffe C.
    Expert Rev Clin Pharmacol; 2018 Mar 24; 11(3):209-217. PubMed ID: 29338466
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
    Nagano M, Susuta Y, Masui H, Watanabe Y, Watanabe K.
    J Clin Psychopharmacol; 2018 Mar 24; 44(2):107-116. PubMed ID: 38421921
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).
    Horiguchi J, Watanabe K, Kondo K, Iwatake A, Sakamoto H, Susuta Y, Masui H, Watanabe Y.
    Psychiatry Clin Neurosci; 2022 Nov 24; 76(11):560-569. PubMed ID: 36114799
    [Abstract] [Full Text] [Related]

  • 18. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N.
    Drugs Today (Barc); 2016 Dec 24; 52(12):665-672. PubMed ID: 28276538
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
    O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, Castro-Gayol JC.
    Mov Disord; 2015 Oct 24; 30(12):1681-7. PubMed ID: 26346941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.